fda glp-1 compounding crackdown news proposes a new Compounded GLP-1s: Why doctors worry

Share medical history to ensure safety

Clinical trials demonstrate significant weight reduction, with patients losing approximately 15% of body weight over 68 weeks with semaglutide (STEP 1 trial) and up to 21% with tirzepatide 15 mg over 72 weeks (SURMOUNT-1 trial)

Only by addressing these multiple levels can meaningful progress be made in reducing the unacceptable delays that characterize current endometriosis care

Chronic low-grade inflammation is increasingly recognised as a key contributor to numerous conditions, including cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and certain autoimmune disorders